17 February 2016
Many patients with Parkinson’s Disease (PD) develop mild cognitive impairment (MCI) or dementia. Identifying biomarkers for cognitive impairment could be instrumental in facilitating both early diagnosis of MCI and developing new cognitive-enhancing treatments. New research published in the Journal of Parkinson’s Disease indicates that lower concentrations of α-synuclein in cerebrospinal fluid (CSF) is associated with reduced performance on several cognitive tests.
8 January 2016
Lewy bodies and Lewy neurites are found in the brains of Parkinson’s disease (PD) patients. They consist primarily of fibrils of the protein alpha-synuclein (α-Syn), which self-assembles into fibrils in vitro. If introduced into the human body, these seeds can act as prions and trigger the formation of toxic protein deposits. Because α-Syn fibrils are often used in research, it is important that they are not accidentally transferred to humans or cell cultures. Researchers reporting in the Journal of Parkinson’s Disease describe three cleaning procedures that effectively remove and disassemble these α-synuclein seeds.
4 January 2016
Recent evidence has shown a greater risk of dementia, in particular Alzheimer’s disease (AD), in individuals using anticholinergic medications regularly. These drugs are widely used by older adults to treat bladder dysfunction, mood, and pain, and many of them are available without prescription. Since these drugs are often used to treat both motor symptoms and non-motor symptoms in patients with Parkinson’s Disease (PD), there is concern for increased risk of dementia. Contrary to expectations, a study in the current issue of the Journal of Parkinson’s Disease determined that the cognitive performance of PD patients taking anticholinergic medications did not differ from those who did not.
10 November 2015
Parkinson’s Disease (PD) patients have a five-fold greater risk of carrying genetic mutations in the β-glucocerebrosidase gene (GBA), which are commonly associated with Gaucher disease (GD). Patients with both PD and GD tend to experience earlier onset of PD and more serious cognitive changes than PD patients without the mutations. A new study published in the Journal of Parkinson’s Disease suggests that GD or the presence of GBA mutations may actually shield patients from deficiency in visual color discrimination, which is a hallmark of PD.
10 November 2015
For many years, researchers have been investigating whether there are any associations between Parkinson’s disease (PD) and lifestyle choices such as smoking and coffee and alcohol consumption. In a review published in the Journal of Parkinson’s Disease, the literature concerning alcohol consumption presents conflicting information.
21 October 2015
The Journal of Parkinson’s Disease is proud to announce the publication of Media Editor Jon Palfreman’s newest book: “Brain Storms: The Race to Unlock the Mysteries of Parkinson’s Disease”, a long-overdue, riveting detective story of the race to stop or reverse neurodegenerative conditions like Parkinson's disease, and a passionate, insightful account into the lives of those affected.
24 June 2015
New Study Calls for Partnering of Parkinson’s Disease Research Community with Patient Groups to Improve Effectiveness of Clinical Trials
Despite an urgent need for new medications, clinical trials in Parkinson’s disease (PD) have a relatively low rate of success. The reasons for this are complex, prompting a group of investigators from PD advocacy groups to conduct a survey of the principle stakeholders, PD scientists, patients, and caregivers, to determine some of the underlying barriers. Their results are published in the Journal of Parkinson’s Disease.
24 June 2015
In recent years, an important Parkinson’s disease (PD) research focus has been on gut-related pathology, pathophysiology, and symptoms. Gastrointestinal dysfunction, in particular constipation, affects up to 80% of PD patients and idiopathic constipation is one of the strongest risk-factors for PD. Lifestyle factors such as smoking and coffee consumption, as well as blood urate levels, have been associated with a decreased PD risk.
26 February 2015
Levodopa-Carbidopa Intestinal Gel May Prove More Effective for Long-Term Treatment of Parkinson’s Disease than Standard Levodopa
Although levodopa remains the “gold standard” to effectively control motor deficits in the treatment of early stage Parkinson’s disease (PD), it loses effectiveness as the disease progresses. After four to six years of treatment with oral medications for Parkinson’s disease, about 40% of patients experience lack of muscle control (dyskinesias), end-of-dose wearing off, and fluctuations in “On/Off” states. By nine years of treatment, about 90% will suffer these effects.
25 February 2015
Patients with Parkinson’s disease (PD) often have difficulties with visual acuity in low-contrast images. Because they may have normal high-contrast vision, this is often overlooked during routine eye exams. In the current issue of the Journal of Parkinson’s Disease, researchers report that PD patients had significantly worse vision for low-contrast images at close (40 cm) and far (2 m) distances. Even for high-contrast images, PD patients’ vision was deficient at far distances.